July 25, 2014 11:19 PM ET

Pharmaceuticals

Company Overview of Bend Research Inc.

Company Overview

Bend Research Inc. develops, advances, and commercializes pharmaceutical technologies. It offers formulation and dosage-form support; assists in process development and optimization; manufactures clinical-trial quantities of drug candidates; and advances promising drug candidates from conception through commercialization. The company also provides formulations, including SDDs and hot-melt extrusions; and controlled-release, inhalation, and biotherapeutics technologies. Bend Research Inc. was founded in 1974 and is based in Bend, Oregon. As of October 1, 2013, Bend Research Inc. operates as a subsidiary of Capsugel, Inc.

64550 Research Road

Bend, OR 97701

United States

Founded in 1974

Phone:

541-382-4100

Fax:

541-382-2713

Key Executives for Bend Research Inc.

Chairman
Age: 58
Adviser and Director
Age: 66
Chief Financial Officer
Senior Vice President and General Counsel
Compensation as of Fiscal Year 2014.

Bend Research Inc. Key Developments

Bend Research Inc. Announces Major Investment in Commercial Spray-Dried Dispersion Manufacturing

Bend Research Inc. announced an investment of more than $20 million to expand commercial manufacturing for spray-dried dispersions at its facilities in Bend, Ore. The investment will encompass a facility expansion dedicated to commercial manufacturing with two new high-capacity PSD spray dryer process trains. The new process trains are flexible and bring the capability for appropriate handling of high-risk/high-potency compounds. The investment is part of a comprehensive strategy to provide customers with complete late-stage development, commercial-launch and commercial-production capability at Bend Research. The commercial facility expansion, co-located with the existing GMP development and manufacturing facility, will be completed and validated by mid-2015. Several companies have already indicated that Bend Research has been chosen as the launch site for their new spray-dried dispersion compounds. The investment adds to existing development and GMP of small and mid-sized spray dryers already in service at the company. The new PSD spray dryers are designed for enhanced flexibility and capability. They can be used to generate optimally engineered particles to meet the needs of a given formulation and therapeutic application. In addition, the throughput and efficiency of the spray dryers is enhanced through specific dryer design and equipment innovations. In addition to the new commercial production lines, the company is building a high-capacity PSD spray dryer in its process-development pilot facility. The development process train will be used for scale-up, quality-by-design studies (QbD), and the production of appropriate toxicology study supplies. This new PSD dryer will allow seamless process development and science-based scale-up to an appropriate commercial scale in a non-GMP environment. The development spray dryer addition will be completed and operational in the spring of 2014.

Bend Research Inc. Announces Addition of Capsugel's Xcelodose Precision Powder-Filling Technology to its Drug Development Process

Bend Research Inc. announced the addition of Capsugel's Xcelodose(R) precision powder-filling technology to its drug development process. This patented micro-dosing technology will further enhance Bend Research's recently announced Rapid Advancement of Preclinical Compounds initiative. The technology will also facilitate fast and efficient scale up and transfer of powder-fill formulations within Capsugel's global network of commercial production sites. The Xcelodose(R) 600S precision powder micro-dosing system enables the dispensing of dose weights as low as 100 micrograms, without excipients or bulking agents. This technology is widely established within the pharmaceutical industry for early stage clinical trials and small-scale production. In addition to streamlining and speeding the process of preparing product for clinical trials, the technology can lower costs by reducing the need for additional costly and time-consuming stability studies. It also gives the company the ability to fill capsules in a controlled environment. The Xcelodose(R) technology will have specific applications in Bend Research's oral and inhalation product development. The rapid advancement of spray-dried dispersions (SDD) to the clinic will also benefit from the Xcelodose(R) technology and the overall formulation flexibility of capsule technology. Precision capsule fill capability is imperative for dry powder inhalation drug products. The addition of the Xcelodose(R) technology to the Bend Research drug development technology portfolio further ensures that inhalation drug development can progress from proof of concept through Phase 2 in 20 weeks or less. The use of capsules for early feasibility and first-in-human clinical trials is a key component of the Rapid Advancement of Preclinical Compound initiative. Specifically, this initiative includes proof of concept (POC), feasibility, and scale-up for IND supporting toxicity and stability study analysis, as well as cGMP manufacturing capability.

Bend Research Inc., PATH, and Fraunhofer USA Center for Molecular Biotechnology Announces the Development of New Technology for the Production of Thermostable Vaccines

Bend Research Inc., PATH, and Fraunhofer USA Center for Molecular Biotechnology announced the development of a new technology for the production of thermostable vaccines. Utilizing novel formulation and spray-drying processing methods, the technology has enabled scientists at Bend Research, PATH, and FhCMB to develop a spray-dried influenza vaccine product that is stable at 50degC for over 2 months. The technology can also be applied to emerging influenza and other vaccines. Thermostable influenza vaccines hold promise for improving the pandemic preparedness of national immunization programs by extending product shelf life, decreasing the cost of vaccine stockpiling, and easing the deployment of vaccines against pandemic influenza strains in the United States or developing countries. Thermostable vaccines can also help to ensure vaccine potency in remote areas of the world with limited to no electricity for cold chain refrigeration. Spray-drying processing methods are well-established for the development and manufacture of pharmaceuticals and dry food products but have rarely been applied to vaccines--until now. The next phase of technical work for the Bend Research Inc., PATH, and FhCMB partnership includes developing a commercially viable process for producing thermostable influenza vaccines using this breakthrough technology. All research activities under the partnership are supported with a grant from the Defense Threat Reduction Agency of the United States Department of Defense and leverages earlier proof-of-concept work advanced by PATH.

Similar Private Companies By Industry

Company Name Region
QuaDPharma, Inc. United States
LarreaRX Inc. United States
Intendis, Inc. United States
InfoQuest Clinical Network, Inc. United States
Blue Ash Therapeutics, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
September 5, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Bend Research Inc., please visit www.bendres.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.